Next Article in Journal
Efficient Approach for the Extraction and Identification of Red Pigment from Zanthoxylum bungeanum Maxim and Its Antioxidant Activity
Previous Article in Journal
Xanthine Oxidase Inhibitory Activity and Thermostability of Cinnamaldehyde-Chemotype Leaf Oil of Cinnamomum osmophloeum Microencapsulated with β-Cyclodextrin
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

C19-Norditerpenoid Alkaloids from Aconitum szechenyianum

1
The College of Life Sciences, Northwest University, Xi’an 710069, China
2
Shaanxi Collaborative Innovation Center of Chinese Medicinal Resource Industrialization, School of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang 712046, China
3
Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
4
Shaanxi Institute for Food and Drug Control, Xi’an 710065, China
5
Department of Pharmacy, Xi’an Medical University, Xi’an 710021, China
*
Authors to whom correspondence should be addressed.
These authors contribute equally to this work.
Molecules 2018, 23(5), 1108; https://doi.org/10.3390/molecules23051108
Submission received: 5 March 2018 / Revised: 25 April 2018 / Accepted: 25 April 2018 / Published: 8 May 2018

Abstract

:
Three new C19-norditerpenoid alkaloids (1–3), along with two known C19-norditerpenoid alkaloids (4,5), have been isolated from Aconitum szechenyianum. Based on extensive spectroscopic techniques (1D, 2D-NMR, IR, and MS) and chemical methods, their structures were established as szechenyianine D (1), szechenyianine E (2), szechenyianine F (3), 8-O-methyl-14-benzoylaconine (4), and spicatine A (5). The immunosuppressive effects of compounds 15 were studied using a ConA-induced or LPS-induced splenocyte proliferation model. In vitro tests showed that Compounds 2, 4, and 5 suppressed ConA-induced or LPS-induced splenocyte proliferation in a concentration-dependent manner. The CC50/IC50 values of 2, 4, and 5 suggested that these compounds were potential immunosuppressive agents for the treatment of autoimmune diseases characterized by arthritis, such as rheumatoid arthritis.

1. Introduction

The roots of Aconitum szechenyianum Gay. and A. flavum Hand.-Mazz., which belong to the Aconitum genus of Ranunculaceae, are widely used in folk medicine in Shaanxi province in China [1]. C19- and C20-diterpenoid alkaloids possessing aconitine-type, 7,17-secoaconitine-type, and napeline-type skeletons, which are the main components of A. szechenyianum [2,3,4,5], possess anti-inflammatory, analgesic, anticancer, anti-epileptiform, and antiparasitic activities [6,7,8]. A. szechenyianum has been preliminarily studied; in that study, several norditerpenoid alkaloids were obtained with an aconitine or 7,17-secoaconitine skeleton, and these skeleton were demonstrated to have anti-inflammatory activities in a dose-dependent manner [9]. This paper reports a new investigation on A. szechenyianum, conducted to explore more bioactive lead compounds, and three new, along with two known, C19-norditerpenoid alkaloids—szechenyianine D (1), E (2), F (3), 8-O-methyl-14-benzoylaconine [10] (4), and spicatine A [11] (5)—were isolated in different fractions from the previous study (Figure 1). The previous study shows that the active ingredients of A. flavum exhibit immunosuppressive effects [12,13], which had not been previously reported from A. szechenyianum. Therefore, the immunosuppressive effects of Compounds 1–5 were evaluated in vitro through ConA- or LPS-induced splenocyte proliferation models. Three compounds inhibited ConA- or LPS-induced splenocyte proliferation, revealing for the first time that the roots of A. szechenyianum possess immunosuppressive activities.

2. Results

Szechenyianine D (1) was isolated as a white amorphous powder and showed a positive reaction with Dragendorff′s reagent. Its molecular formula C31H43NO10 was derived from the protonated molecular ion peak at m/z 590.2979 [M + H]+ (calcd. 590.2965) in the HR-ESI-MS spectrum. The 1H-NMR spectrum (Table 1) of 1 showed the presence of five aromatic proton signals due to a monosubstituted benzene at δH 8.00 (2H, d, J = 7.4 Hz), 7.54 (1H, t, J = 7.4 Hz), and 7.44 (2H, t, J = 7.4 Hz), five OMe protons at δH 3.80(3H, s), 3.37 (3H, s), 3.29 (over-lapped), 3.29 (over-lapped), and 3.21 (3H, s), and two strongly shielded protons at δH 3.32 (1H, s) and δH 4.29 (1H, s). The 13C-NMR spectrum (Table 1) displayed 31 carbon resonances. Among them, resonances at δC 166.4, 133.4, 130.0, 130.0 (C × 2), and 128.7 (C × 2) were attributed to a benzoyloxy group; δC 62.2, 59.3, 59.0, 55.4, and 50.7 were attributed to five OMe groups; δC 74.7 and 76.4 were attributed to two oxygenated carbons associated with hydroxyl groups. Out of the 10 oxygen atoms in 1, 9 are associated with five methoxy groups, two hydroxyl groups, and one benzoyl group, and the remaining one may be a hydroxyl group or an internal ether. The NMR features of the remaining 19 resonances were characteristic of an aconitine-type alkaloid, where the δC 64.4 and 70.0 resonances were attributed to the two carbons associated with an internal ether. The deduction was confirmed by the chemical shift of C-7 (δC 64.4) and C-17 (δC 70.0) to downfield in 13C-NMR spectra of 1 compared with C-7 (δC 49.6) and C-17 (δC 60.6) of szechenyianine A [9], the signals of which are shielded by oxygen atom. In the HMBC spectrum (Figure 2), correlations of H-5 (δH 2.41) and H-6 (δH 4.12) to C-7 (δC 64.4), and H-1 (δH 3.45) to C-17 (δC 70.0), suggested the involvement of an internal ether bond. The correlation of H-14 (δH 4.84) to the carbonyl carbon signal of the benzoyl group (δC 166.4) suggested that the benzoyl group was located at C-14. The correlations of OCH3H 3.37) to C-1 (δC 80.3), OCH3H 3.29) to C-6 (δC 82.2), OCH3H 3.21) to C-8 (δC 83.3), OCH3H 3.80) to C-16 (δC 93.2), and OCH3H 3.29) to C-18 (δC 76.6) suggested that five methoxyl groups were linked at C-1, C-6, C-8, C-16, and C-18. The correlations of H-12 (δH 1.84, 2.24) and H-14 (δH 4.84) to C-13 (δC 74.7), and H-16 (δH 3.22) to C-15 (δC 76.4), suggested that two hydroxyl groups were linked at C-13 and C-15. Thus, the planar structure of 1 was deduced as 14-benzoyloxy-13, 15-dihydroxy-1, 6,8,16,18-pentamethoxyl-7(17)-oxide-aconitane. In the ROESY spectrum (Figure 2) of 1, the NOE correlations of H-1/H-3, H-3/H-5, H-5/H-10, H-10/H-9, H-10/H-14, H-14/H-9, and H-9/H-6 indicated β-orientation of H-1, H-5, H-6, H-9, H-10, and H-14, and α-axial configurations of 1-OCH3, 6-OCH3, and 14-benzoyloxy. NOE correlations of H-6/H-5 and H-5/H-18 revealed β-orientation of H-18 and 18-OCH3; NOE correlations of H-17/H-7, H-15/16-OCH3 revealed α-axial orientation of H-16, H-17, and 15-OH and β-orientation of 16-OCH3, 13-OH, and 8-OCH3. Moreover, the NOE correlations of H-1/H-3 and H-5 and the lack of correlation between H-2 and H-5 indicated that ring A (C-1, C-2, C-3, C-4, C-5, and C-11) in 1 was in the chair conformation. Thus, Compound 1 was assigned the name (A-c)-14α-benzoyloxy-13β,15α-dihydroxy-1α,6α,8β,16β,18β-pentamethoxy-7(17)-oxide-aconitane.
Szechenyianine E (2) was isolated as a white amorphous powder and showed a positive reaction with Dragendorff′s reagent. Its molecular formula C39H55NO11 was derived from the protonated molecular ion peak at m/z 714.3840 [M + H]+ (calcd.714.3853) in the HR-ESI-MS spectrum. The 1H-NMR spectrum (Table 1) of 2 showed the presence of five aromatic proton signals due to a monosubstituted benzene at δH 8.01 (2H, d, J = 7.5 Hz), 7.56 (1H, t, J = 7.5 Hz), 7.45 (2H, t, J = 7.5 Hz), four OMe protons at δH 3.75 (3H, s), 3.30 (3H, s), 3.19 (3H s), and 3.12 (3H, s); one acetoxyl proton at δH 1.35 (3H, s), and one methylic proton of the hydrocarbon chain at δH 0.86 (3H, t, J = 6.2 Hz). The 13C-NMR spectrum (Table 1) displayed 39 carbon resonances. Among them, the resonances at δC 166.2, 133.6, 129.9, 129.8 (C × 2), and 128.9 (C × 2) were attributed to a benzoyloxy group; δC 61.5, 59.4, 58.0, and 55.5 were attributed to four OMe groups, δC 172.5 and 21.6 were attributed to one acetoxyl group; δC 173.3 was attributed to C=O, δC 74.3 and 79.0 were attributed to two carbons associated with the hydrocarbon chain, and δC 14.3 was attributed to one CH3 group. The assignments of the NMR signals associated with 2 were derived from HSQC, HMBC, and ROESY experiments. In the HMBC spectrum (Figure 3), correlations of H-14 (δH 4.89) to the carbonyl carbon signal of the benzoyl group (δC 166.4) suggested that the benzoyl group was located at C-14. Correlations of OCH3H 3.19) to C-1 (δC 82.4), OCH3H 3.12) to C-6 (δC 83.3), OCH3H 3.75) to C-16 (δC 90.4), and OCH3H 3.30) to C-18 (δC 80.0) suggested that four methoxyl groups were linked at C-1, C-6, C-16, and C-18, respectively. Correlations of CH3H 1.32) to 8-OAc (δC 172.5) suggested that one acetoxyl was linked at C-8, and correlations of H-3 (δH 2.61, 2.71), H-17 (δH 4.11), and H-20 (δH 3.04, 3.92) to C-19 (δC 173.3) suggested that C=O was linked at C-19. Correlations of H-20 (δH 3.04, 3.92) to C-17 (δC 56.7) and C-21 (δC 33.7), H-21 (δH 1.51, 1.62) to C-22 (δC 25), and H-22 (δH 1.59, 1.68), H-25 (δH 1.30, 2H, m), and H-26 (δH 0.86, 3H, t) to C-24 (δC 31.9) suggested the presence of an N-heptyl group. Correlations of H-12 (δH 2.19, 2.80), H-14 (δH 4.89), and H-16 (δH 3.30) to C-13 (δC 74.3), and H-16 (δH 3.30) to C-15 (δC 79.0) suggested that two hydroxyl groups were linked at C-13 and C-15, respectively. This compound differed from the known compound (A-c)-8β-acetoxy-14α-benzoyloxy-N-ethyl-13β,15α-dihydroxy-1α,6α,16β,18β-tetramethoxy-19-oxo-aconitane [14] only in terms of the substituents on the N atom. According to the ROESY (Figure 3) spectrum, NOE correlations of H-6/H-5 and H-5/H-18 revealed β-orientation of H-18 and 18-OCH3, α-axial orientation of 6-OCH3; NOE correlations of H-7/H-15, H-17/H-16 revealed α-axial orientation of H-16, H-17, and 15-OH and β-orientation of 16-OCH3, 13-OH, and 8-OAc. Moreover, the NOE correlations of H-3/H-1/H-10/H-9/H-6/H-5 and the lack of correlation between H-2 and H-5 indicated that Ring A (C-1, C-2, C-3, C-4, C-5, and C-11) in 2 was in the chair conformation, the relative configuration of this compound was confirmed. Thus, the planar structure of 2 was assigned the name (A-c)-14α-benzoyloxy-8β-acetoxyl-N-heptyl-13β,15α-dihydroxy-1α,6α,16β,18β-tetramethoxy-19-oxo-aconitane.
Szechenyianine F (3) was isolated as a white amorphous powder and showed a positive reaction with Dragendorff′s reagent. Its molecular formula C24H38NO5+ was derived from the ion peak at m/z 421.2782[M]+ (calcd.421.2823) in the HR-ESI-MS spectrum. The 1H-NMR spectrum (Table 1) of 3 showed the presence of a methine proton due to one N=CH group at δH 9.19 (1H, s), one N–CH2CH3 group at δH 1.51 (t, J =7.2 Hz), 4.01 (dq, J =7.2, 13.9 Hz ), and 4.42 (dq, J =7.2, 13.8 Hz), and three OMe resonances at δH 3.38 (3H, s), 3.36 (3H, s), and 3.16 (3H, s). The 13C-NMR spectrum (Table 1) displayed 24 carbon resonances. Among them, the resonances at δC 59.8, 56.9, and 56.7 were attributed to three OMe groups, δC 179.2 was attributed to one N=CH group, and δC 14.0 and 56.3 were attributed to one N–CH2CH3 group. Comparison of the NMR data of N–CH2CH3 and C-19 with those of the known compound 11 in [15] indicated the existence of the N=CH group. The assignments of the NMR signals associated with 3 were based on HSQC, HMBC, and ROESY experiments. In the HMBC spectrum (Figure 4), correlations of H-5 (δH 2.46) and H-17 (δH 3.79) to C-19 (δC 179.2) suggested that C-19 was involved in the N=CH group. Correlations of OCH3H 3.18) to C-1 (δC 80.6), OCH3H 3.36) to C-16 (δC 81.5) and of OCH3H 3.38) to C-18 (δC 73.4) suggested that three methoxyl groups were linked at C-1, C-16, and C-18, respectively. Correlations of H-6 (δH 1.82, 2.20), H-7 (δH2.22), H-9 (δH 2.47), and H-10 (δH 2.01) to C-8 (δC 72.3) and of H-16 (δH 3.45) to C-14 (δC 75.0) suggested that two hydroxyl groups were linked at C-8 and C-14, respectively. Thus, the planar structure of 3 was deduced as 8,14-dihydroxy-1,16,18-trimethoxy-19-en-aconitane. In the ROESY spectrum (Figure 4) of 3, the NOE correlations of H-1/H-5, H-1/H-10, and H-10/H-14 indicated β-orientation of H-1, H-9, H-10, and H-14, and α-axial configurations of 1-OCH3, 14-OH. NOE correlations of H-5/H-18 indicated β-orientation of H-18 and 18-OCH3. NOE correlations of H-17/H-12, H-12/H-16, and H-15/H-16 indicated α-axial configurations of H-16, H-17, and 16-OCH3 and β-orientation of 8-OH. Thus, Compound 3 was assigned the name 8β,14α-dihydroxy-1α,16β,18β-trimethoxy-19-en-aconitane.
The roots of A. szechenyianum have long been used to treat rheumatic diseases, in which inflammation and suppressive immunoreaction are involved in the pathophysiological process. The immunosuppressive effects of Compounds 15 were evaluated in vitro by ConA-induced or LPS-induced splenocyte proliferation, which was suppressed in a concentration-dependent manner by 2, 4, and 5 (Figure 5b,c), with IC50 values of 5.780 ± 1.12 μm, 3.151 ± 0.52 μm, and 2.644 ± 0.77 μm (ConA-induced), or 4.293 ± 3.20 μm, 3.852 ± 1.57 μm, and 2.283 ± 1.28 μm (LPS-induced), respectively. These three compounds showed low cytotoxic effect (Figure 5a), with CC50 values of 422.85 ± 66.4 μm, 176.35 ± 69.65 μm, and 188 ± 84.15 μm, respectively. The CC50/IC50 values of 2, 4, and 5 suggested that these compounds are potential immunosuppressive agents.
These three compounds had a certain immunosuppressive effects, but low cytotoxic effects compared with cyclosporin A. We will conduct further experiments in vivo using the arthritis model in rat induced by adjuvant and arthritis model in mice induced by collagen, to obtain more lead compounds to treat rheumatoid arthritis.

3. Materials and Methods

3.1. General Information

Optical rotation indices were determined in methanol on a Rudolph Autopol II digital polarimeter (Rudolph, Hackettstown, NJ, USA). ESI-MS analysis was performed on a Quatro Premier instrument (Waters, Milford, MA, USA). HR-ESI-MS spectra were recorded on an Agilent Technologies 6550 Q-TOF (Santa Clara, CA, USA). 1D- and 2D-NMR spectra were recorded on Bruker-AVANCE 400 (Bruker, Rheinstetten, Germany) and Bruker-AVANCE 600 instrument (Bruker, Rheinstetten, Germany) using TMS as an internal standard. Analytical HPLC was performed on a Waters e2695 Separations Module system coupled with a 2998 Photodiode Array Detector and an Accurasil C-18 column (4.6 mm × 250 mm, 5 μm particles, Ameritech, Chicago, IL, USA). Semipreparative HPLC was performed on a system comprising an LC-6AD pump equipped with an SPD-20A UV detector (Shimadzu, Kyoto, Japan) and an Ultimate XB-C18 (10 mm × 250 mm, 5 μm particles) or YMS-Pack-ODS-A (10mm × 250 mm, 5 μm particles) column. Silica gel was purchased from Qingdao Haiyang Chemical Group Corporation (Qingdao, China).

3.2. Plant Material

The roots of A. szechenyianum Gay. were collected from the Xi Mountains in Gansu Province of China in July 2014 and identified by senior experimentalist Jitao Wang. A voucher specimen (herbarium No. 20140728) has been deposited in the Medicinal Plants Herbarium (MPH), Shaanxi University of Chinese Medicine, Xianyang, China.

3.3. Extraction and Isolation

The air-dried and powdered underground parts of A. szechenyianum (5.0 kg) were extracted with 80% EtOH at 80 °C (3 × 40 L; 1.5 h). After the removal of EtOH under reduced pressure, the extract (2 L) was dispersed in water (1.5 L), adjusted to pH 0.8 with 9% HCl solution, and extracted with petroleum ether (PE). The acidic water solution was alkalized to pH 10.26 with 25% ammonia solution, extracted with CHCl3 three times, and evaporated under pressure to give crude alkaloids (50 g). The crude alkaloids (47 g) were loaded on a silica gel column and eluted with a gradient solvent system (PE/acetone/diethylamine, 50:1:0.1–1:1:0.1) to yield 12 fractions (Fr.1–Fr.12). Fr.3 (2.5 g) was purified by HPLC (YMC-Pack-ODS-A, 10 × 250 mm, 5 μm particles, flow rate of 1.0 mL·min−1) with CH3OH/H2O (83:17) as the mobile phase to obtain 1 (6 mg, tR = 45 min). Fr.4 was purified by HPLC with CH3OH/H2O (75:25) as the mobile phase to obtain 4 (60 mg, tR = 46 min) and 5 (40 mg, tR = 58 min). Fr.7 was purified by HPLC with CH3OH/H2O (65:35) as the mobile phase to obtain 2 (7 mg, tR = 50 min) and 3 (7 mg, tR = 56 min). More details of the spectra are provided in the Supplementary Material.
(A-c)-14α-benzoyloxy-8β-acetoxyl-13β,15α-dihydroxy-1α,6α,8β,16β,18β-pentamethoxyl-7(17)–oxide-aconitane (szechenyianine D): A white amorphous powder, [α ] D 23.1 -9.3 (c 0.043, MeOH), IR (KBr) νmax: 3495, 2914, 1719, 1277, 1099, 1031 and 712 cm−1; 1H-NMR (400 MHz, CDCl3) and 13C-NMR (100 MHz, CDCl3) spectral data, see Table 1; m/z 590.2979 [M + H]+ (calcd. 590.2965) for C31H43NO10.
(A-c)-14α-benzoyloxy-8β-acetoxy-N-nonyl-13β,15α-dihydroxy-1α,6α,16β,18β-tetramethoxy-19-oxo-aconitane (szechenyianine E): A white amorphous powder, [α ] D 23.0 + 12.1 (c 0.033, MeOH), IR (KBr) νmax: 3471, 2933, 2822, 1717, 1453, 1278, 1098, and 712 cm−1; 1H-NMR (600 MHz, CDCl3) and 13C-NMR (150 MHz, CDCl3) spectral data, see Table 1; m/z 714.3840 [M + H] + (calcd.714.3853) for C39H55NO11.
8β,14α-dihydroxy-1α,16β,18β-trimethoxy-19-en-aconitane (szechenyianine F): A white amorphous powder, [α ] D 22.9 -17.4 (c 0.013, MeOH), IR (KBr) νmax: 3381, 2933, 1630, 1455, 1376, 1096, and 1030 cm−1; 1H-NMR (400 MHz, CDCl3) and 13C-NMR (100 MHz, CDCl3) spectral data, see Table 1; m/z 421.2782 [M]+ (calcd.421. 2823) for C24H38NO5+.

3.4. MTT Assay

Splenocytes (4 × 105 cells/well) were incubated in triplicate at 37 °C in a humidified incubator with 5% CO2 and 95% air. The assay was performed in a 96-well format, and different concentration of Compounds 15 (0.16–100 μm) and CsA(2μm)were added. The cells cultured with media alone were used as controls. Approximately 48 h later, 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (5 mg/mL, Sigma) was added to each well. The plates were then incubated for another 5 h. Approximately 150 μL of DMSO (Sigma) was then added to each well. Optical density was measured at 570 nm (BioTek, PowWave XS2, VT, USA). The IC50 and CC50 values were calculated according to the dose curves generated by plotting the percentage of viable cells against the test concentration on a logarithmic scale by using SPSS 15.0. CsA (Cyclosporine A, Sigma, Chicago, IL, USA) was used as a positive control.

3.5. ConA- and LPS-Induced Assay

Splenocytes (4 × 105 cells/well), different concentration of Compounds 15 (0.16–100 μm), and CsA(2 μm)in 96-well plates at 37 °C in a 5% CO2 atmosphere were cultured in triplicate for 48 h using ConA (2 μg/mL, Sigma) or LPS (1 μg/mL, Sigma). The cells cultured with media alone were used as controls. The cells were pulsed at 0.25 μCi/well of [3H]-thymidine for 8 h before the end of the culture period and then harvested onto glass fiber filters. [3H]-thymidine incorporation was measured using a beta scintillation counter (MicroBeta Trilux, PerkinElmer Life Sciences, Boston, MA, USA).

Supplementary Materials

The spectra of Compounds 13 are available online at https://www.mdpi.com/1420-3049/23/5/1108/s1.

Author Contributions

Every author participated in the research and contributed to the article: B.S. and B.J. conducted the experiments and collected the data; Y.L., F.W., and Y.C. coordinated the experiments; Z.Y. analyzed the data; X.S. and Y.Y. designed the study; J.L. planned and oversaw the research project and drafted the paper. Finally, all authors read and approved the final manuscript.

Funding

This research was funded by the National Natural Science Foundations of China (grant No. 81102805, 81373978), the Open Projects Program of the Key Laboratory of Tibetan Medicine Research, Chinese Academy of Sciences (grant No. 2014-TMR-01), the Program of Shannxi Provincial Department of Education (grant No. 15JK1204), and the Innovative Research Team in TCM Material Foundation and Key Preparation Technology (grant No. 2012KCT-20).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Song, X.M.; Liu, H.J. Research and Application of “Qi-Medicines” in Taibai Mountains; People’s Medical Publishing House: Beijing, China, 2011. [Google Scholar]
  2. Fan, Z.C.; Zhang, Z.Q. Crystal and molecular structure of songorine from the aoot of Aconitum szechenyianum Gay. J. Chem. Crystallogr. 2008, 38, 635–639. [Google Scholar] [CrossRef]
  3. Wang, Y.J.; Zeng, C.J.; Yao, Z.; Zhang, J.; Zhang, Y.; Zhang, F. Diterpene alkaloids from roots and processed products of Aconitum pendulum. Chin. Tradit. Herb. Drugs 2010, 41, 347–351. [Google Scholar]
  4. Liu, L.M.; Wang, H.C.; Zhu, Y.L. Studies on Chinese drug Aconitum spp. XIX. The alkaloids of Aconitum pendulum and their chemical structure. Yao Xue Xue Bao 1983, 18, 39–44. [Google Scholar] [PubMed]
  5. Wang, Y.J.; Zhang, J.; Zeng, C.J.; Yao, Z.; Zhang, Y. Three new C19-diterpenoid alkaloids from Aconitum pendulum. Phytochem. Lett. 2011, 4, 166–169. [Google Scholar] [CrossRef]
  6. Wada, K.; Ohkoshi, E.; Morris-Natschke, S.L.; Bastow, K.F.; Lee, K.H. Cytotoxic esterified diterpenoid alkaloid derivatives with increased selectivity against a drug-resistant cancer cell line. Bioorg. Med. Chem. Lett. 2012, 22, 249–252. [Google Scholar] [CrossRef] [PubMed]
  7. Yuan, J.F.; Zhang, Z.Q.; Kang, X.; Liu, J.L. LC-MS analysis for the components captured by ECV304 cell from extract of Aconitum szechenyianum Gay. Biomed. Chromatogr. 2009, 23, 406–411. [Google Scholar] [CrossRef] [PubMed]
  8. Fan, Y.; Jiang, Y.; Liu, J.; Kang, Y.; Li, R.; Wang, J. The anti-tumor activity and mechanism of alkaloids from Aconitum szechenyianum Gay. Bioorg. Med. Chem. Lett. 2015, 26, 380–387. [Google Scholar] [CrossRef] [PubMed]
  9. Wang, F.; Yue, Z.G.; Xie, P.; Zhang, L.; Li, Z.; Song, B.; Tang, Z.; Song, X.M. C19-Norditerpenoid Alkaloids from Aconitum szechenyianum and Their Effects on LPS-Activated NO Production. Molecules 2016, 21, 1175. [Google Scholar] [CrossRef] [PubMed]
  10. Wang, X.K.; Zhao, T.F.; Lai, S. Alkaloids of cultivated Aconitum carmichaeli I. Chin. Pharm. J. 1995, 30, 716–719. [Google Scholar]
  11. Gao, L.M.; Wei, X.M.; Yang, L. Two New Norditerpenoid Alkaloids from Aconitum spicatum Stapf. Chin. Chem. Lett. 2005, 16, 475–478. [Google Scholar]
  12. Kang, X.L. Study on therapeutic effect of the effective parts of Aconitum flavum on Adjuvant arthritis in rats; Ningxia Medical university: Ningxia, China, 2013. [Google Scholar]
  13. Fu, X.Y.; Yu, L.; Kang, X.L.; Dong, L.; Zhang, Y.; Chen, J. Study on therapeutic effect and mechanism of the non-alkaloid fraction of Aconitum flavumn on Adjuvant arthritis in rats. Chin. Med Mater. 2014, 37, 312–315. [Google Scholar]
  14. Jiang, B.; Lin, S.; Zhu, C.; Wang, S.; Wang, Y.; Chen, M.; Zhang, J.; Hu, J.; Chen, N.; Yang, Y. Diterpenoid alkaloids from the lateral root of Aconitum carmichaelii. J. Nat. Prod. 2012, 75, 1145–1159. [Google Scholar] [CrossRef] [PubMed]
  15. Shen, X.L.; Wang, F.P. New products from the reaction of acetyllycoctonine with N-bromosuccinimide (NBS). Chem. Pharm. Bull. 2004, 52, 1095–1097. [Google Scholar] [CrossRef] [PubMed]
Sample Availability: Samples of the compounds 45 are available from the authors.
Figure 1. Structures of Compounds 15.
Figure 1. Structures of Compounds 15.
Molecules 23 01108 g001
Figure 2. Key HMBC (H→C) and ROESY (H↔H) correlations of Compound 1.
Figure 2. Key HMBC (H→C) and ROESY (H↔H) correlations of Compound 1.
Molecules 23 01108 g002
Figure 3. Key HMBC (H→ C) and ROESY (H↔H) correlations of Compound 2.
Figure 3. Key HMBC (H→ C) and ROESY (H↔H) correlations of Compound 2.
Molecules 23 01108 g003
Figure 4. Key HMBC (H→C) and ROESY (H↔H) correlations of Compound 3.
Figure 4. Key HMBC (H→C) and ROESY (H↔H) correlations of Compound 3.
Molecules 23 01108 g004
Figure 5. Cytotoxicity on splenocytes and inhibition on ConA- or LPS-induced splenocyte proliferation of Compounds 15. (a) Cytotoxicity of Compounds 15 on BALB/c mice splenocytes. (b) Inhibition of Compounds 15 on ConA-induced splenocyte proliferation. (c) Inhibition of Compounds 15 on LPS-induced splenocyte proliferation. Results are mean ± S.D. * p < 0.05, ** p < 0.01, *** p < 0.001, treatment group versus control.
Figure 5. Cytotoxicity on splenocytes and inhibition on ConA- or LPS-induced splenocyte proliferation of Compounds 15. (a) Cytotoxicity of Compounds 15 on BALB/c mice splenocytes. (b) Inhibition of Compounds 15 on ConA-induced splenocyte proliferation. (c) Inhibition of Compounds 15 on LPS-induced splenocyte proliferation. Results are mean ± S.D. * p < 0.05, ** p < 0.01, *** p < 0.001, treatment group versus control.
Molecules 23 01108 g005aMolecules 23 01108 g005b
Table 1. 1H-NMR and 13C-NMR spectral data for Compounds 15.
Table 1. 1H-NMR and 13C-NMR spectral data for Compounds 15.
NO.12345
δCδH (J in Hz)δCδH (J in Hz)δCδH (J in Hz)δCδC
180.33.45 (d, 7.6)82.43.07 (d, 8.3)80.63.40 (m)82.882.8
229.61.22 (m, H-2a)25.31.43 (m, H-2a)20.61.40 (m, H-2a)33.633.6
2.41 (m, H-2b)1.87 (m, H-2b)1.72 (m, H-2b)
329.91.22 (m, H-3a)33.42.61 (m, H-3a)25.51.94 (m)72.071.9
1.40 (m, H-3b)2.71 (m, H-3b)
443.5 37.8 48.6 43.343.2
542.32.41 (d, 6.7)47.62.29 (d, 6.7)38.42.46 (m)46.245.9
682.24.12 (d,6.7)83.34.04 (d, 6.7)24.61.82 (m, H-6a)2.20 (m, H-6b)83.683.7
764.43.32 (s)50.92.63 (s)45.12.22 (m)45.443.3
883.3 91.3 72.3 82.682.5
944.52.59 (t, 5.8)43.52.84 (t, 5.8)53.82.47 (m)42.745.4
1040.82.26 (m)41.12.19 (m)38.32.01 (m)41.741.6
1150.9 50.0 51.2 50.850.8
1235.52.24 (m, H-12a)35.62.80 (m, H-12a)27.82.04 (m, H-12a)1.26 (m, H-12b)36.536.5
1.84 (m, H-12b)2.19 (m, H-12b)
1374.7 74.3 43.31.96 (m)75.075.0
1478.84.84 (d, 5.8)78.84.89 (d, 5.8)75.04.21 (t, 4.9)79.779.8
1576.44.65 (d, 5.4)79.04.49 (dd, 2.9, 5.4)39.52.27 (m, H-15a)78.078.7
2.40 (m, H-15b)
1693.23.22 (d, 5.4)90.43.30 (d, 5.4)81.53.45 (m)93.693.6
1770.04.29 (s)56.74.11 (s)68.13.79 (s)62.761.4
1876.63.54(d, 8.2, H-18a)80.03.78(d,8.2,H-18a)73.43.71 (2H, m)77.277.2
3.46 (d,8.2, H-18b)3.06(d,8.2,H-18b)
1950.33.62(d,11.9,H-19a)173.3 179.29.19 (s)49.249.2
3.72(d,11.9,H-19b)
20 45.53.04 (m, H-20a)
3.92 (m, H-20b)
21 33.71.51 (m, H-21a)
1.62 (m, H-21b)
22 25.01.59 (m, H-22a)
1.68 (m, H-22b)
23 29.61.30 (m, H-23a)
1.23 (m, H-23b)
24 31.91.30 (m, H-24a)
2.26 (m, H-24b)
25 22.91.30 (2H, m)
26 14.30.86 (3H, t,6.2)
8-OAc 172.5
21.61.35 (s)
8-OCH2CH3 57.4
8-OCH2CH3 15.5
1-OCH355.43.37 (s)55.53.19 (s)56.73.16 (s)56.156.1
6-OCH359.33.29 (s)58.03.12 (s) 59.458.8
8-OCH350.73.21 (s) 50.1
16-OCH362.23.80 (s)61.53.75 (s)56.93.36 (s)61.462.6
18-OCH359.03.29 (s)59.43.30 (s)59.83.38 (s)59.359.3
N-CH2CH3 56.34.01 (dq, 13.9, 7.2)47.647.6
4.42 (dq, 13.9, 7.2)
N-CH2CH3 14.01.51 (t, 7.2)13.613.5
ArC=O166.4 166.2 166.5166.4
ArC-1′130.0 129.9 130.4130.6
3′, 5′128.77.44 (t, 7.4)128.97.45 (t, 7.5) 128.6128.6
2′, 6′130.08.00 (d, 7.4)129.88.01 (d, 7.5) 129.9129.9
4′133.47.54 (t, 7.4)133.67.56 (t, 7.5) 133.1133.1
δ in CDCl3, in ppm from TMS; coupling constants (J) in Hz; 1H-NMR at 400 MHz and 13C-NMR at 100 MHz for Compounds 1, 3, 4, and 5, and 1H-NMR at 600 MHz and 13C-NMR at 150 MHz for Compound 2.

Share and Cite

MDPI and ACS Style

Song, B.; Jin, B.; Li, Y.; Wang, F.; Yang, Y.; Cui, Y.; Song, X.; Yue, Z.; Liu, J. C19-Norditerpenoid Alkaloids from Aconitum szechenyianum. Molecules 2018, 23, 1108. https://doi.org/10.3390/molecules23051108

AMA Style

Song B, Jin B, Li Y, Wang F, Yang Y, Cui Y, Song X, Yue Z, Liu J. C19-Norditerpenoid Alkaloids from Aconitum szechenyianum. Molecules. 2018; 23(5):1108. https://doi.org/10.3390/molecules23051108

Chicago/Turabian Style

Song, Bei, Bingliang Jin, Yuze Li, Fei Wang, Yifu Yang, Yuwen Cui, Xiaomei Song, Zhenggang Yue, and Jianli Liu. 2018. "C19-Norditerpenoid Alkaloids from Aconitum szechenyianum" Molecules 23, no. 5: 1108. https://doi.org/10.3390/molecules23051108

Article Metrics

Back to TopTop